Nuclear translocation of the cytoplasmic domain of HB-EGF induces gastric cancer invasion by Takaya Shimura et al.
Shimura et al. BMC Cancer 2012, 12:205
http://www.biomedcentral.com/1471-2407/12/205RESEARCH ARTICLE Open AccessNuclear translocation of the cytoplasmic domain
of HB-EGF induces gastric cancer invasion
Takaya Shimura1*, Michihiro Yoshida1, Shinji Fukuda2, Masahide Ebi1, Yoshikazu Hirata1, Tsutomu Mizoshita1,
Satoshi Tanida1, Hiromi Kataoka1, Takeshi Kamiya1, Shigeki Higashiyama2,3 and Takashi Joh1Abstract
Background: Membrane-anchored heparin-binding epidermal growth factor-like growth factor (proHB-EGF) yields
soluble HB-EGF, which is an epidermal growth factor receptor (EGFR) ligand, and a carboxy-terminal fragment of
HB-EGF (HB-EGF-CTF) after ectodomain shedding. We previously reported that HB-EGF-CTF and unshed proHB-EGF
which has the cytoplasmic domain of proHB-EGF (HB-EGF-C), translocate from the plasma membrane to the
nucleus and regulate cell cycle after shedding stimuli. However, the significance of nuclear exported HB-EGF-C in
human gastric cancer is unclear.
Methods: We investigated the relationship between intracellular localization of HB-EGF-C and clinical outcome in
96 gastric cancer patients treated with gastrectomy. Moreover, we established stable gastric cancer cell lines
overexpressing wild-type HB-EGF (wt-HB-EGF) and mutated HB-EGF (HB-EGF-mC), which prevented HB-EGF-C
nuclear translocation after shedding. Cell motility between these 2 gastric cancer cell lines was investigated using a
transwell invasion assay and a wound healing assay.
Results: Of the 96 gastric cancer cases, HB-EGF-C immunoreactivity was detected in both the nucleus and
cytoplasm in 19 cases (19.8 %) and in the cytoplasm only in 25 cases (26.0 %). The nuclear immunoreactivity of HB-
EGF-C was significantly increased in stage pT3/4 tumors compared with pT1/2 tumors (T1/2 vs. T3/4: 11.1 % vs.
36.4 %, P< 0.01). The growth of wt-HB-EGF- and HB-EGF-mC-expressing cells significantly increased compared with
control cells, but the growth of HB-EGF-mC-expressing cells was significantly decreased compared with wt-HB-EGF-
expressing cells. Gastric cancer cell invasion obviously increased in wt-HB-EGF-expressing cells, but invasion in HB-
EGF-mC-expressing cells showed a slight increase compared with control cells. Moreover, wt-HB-EGF overexpression
increased the effectiveness of wound healing, but had no significant effect in HB-EGF-mC-expressing cells.
Conclusions: Both the function of HB-EGF as an EGFR ligand and a novel signal for HB-EGF-C nuclear translocation
induce gastric cancer growth, whereas HB-EGF-C nuclear translocation independently plays a critical role in gastric
cancer invasion. The present study demonstrated that HB-EGF-C nuclear translocation might be crucial in gastric
cancer invasion. HB-EGF-C nuclear translocation may offer a prognostic marker and a new molecular target for
gastric cancer therapy.
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Gastric cancer is the fourth most common malignancy
and the second leading cause of cancer death in the
world [1]. Despite the recent development of several
novel cytotoxic agents, the prognosis of advanced gastric
cancer remains poor, and new treatments that show ac-
ceptable toxicity profiles are urgently needed. No mo-
lecular target agent has shown sufficient clinical effects
in gastric cancer, but trastuzumab, a monoclonal anti-
body that targets human epidermal growth factor recep-
tor 2 (HER2; also known as ERBB2), was recently shown
in a global phase III clinical trial to confer a survival
benefit for HER2-positive advanced gastric cancer [2].
Although this molecular target agent was clinically
approved for use in gastric cancer therapy, further devel-
opment of biomarkers should be pursued because only
approximately 20 % of all gastric cancers expressing
HER-2. The epidermal growth factor receptor (EGFR)
belongs to the ErbB receptor tyrosine kinase family,
which includes erbB1 (EGFR), erbB2 (HER2), erbB3
(HER3), and erbB4 (HER4). EGFR plays a key role in can-
cer regulation. EGFR has 7 known ligands, all of which
are synthesized as type I transmembrane protein precur-
sors and are subsequently expressed on the plasma mem-
brane [3]. The increased expression of EGFR ligands,
including transforming growth factor TGF-α, heparin-
binding EGF-like growth factor (HB-EGF), and amphire-
gulin, is associated with clinical prognosis in many can-
cers such as gastric cancer [4,5].Figure 1 Nuclear translocation of HB-EGF-C. Membrane-anchored hepa
yields soluble HB-EGF (sHB-EGF) and a carboxy-terminal fragment of HB-EG
a ligand and activates the downstream signal pathways. HB-EGF-CTF transl
cytoplasmic domain of HB-EGF (HB-EGF-C) binds to some transcriptional re
the nucleus after shedding stimuli. HB-EGF-C is included in both HB-EGF-CTMembrane-anchored HB-EGF (proHB-EGF), an EGFR
ligand, is cleaved from the plasma membrane in a
process termed ectodomain shedding, which yields sol-
uble HB-EGF (s-HB-EGF) and a carboxy-terminal frag-
ment of HB-EGF (HB-EGF-CTF) (Figure 1). s-HB-EGF
binds to EGFR and induces activation of intracellular sig-
naling cascades that are implicated in the regulation of a
wide variety of cellular processes, including growth, dif-
ferentiation, apoptosis, adhesion, and migration. We pre-
viously showed HB-EGF-CTF translocates from plasma
membrane to the nucleus after ectodomain shedding of
proHB-EGF and regulates cyclin A and cyclin D2 by the
cytoplasmic domain of proHB-EGF (HB-EGF-C) binding
to transcriptional repressors, such as promyelocytic
leukemia zinc finger (PLZF) and B-cell lymphoma 6 (Bcl6)
[6,7]. We previously showed that BCL6 expression is
linked to the downregulation of cyclin D2 in HB-EGF-
positive human gastric cancer cells [8]. Moreover, we have
shown in vitro that suppression of HB-EGF-CTF nuclear
translocation may be a new molecular target for gastric
cancer therapy [9]. Subsequently, we showed that not only
HB-EGF-CTF but also unshed proHB-EGF translocate to
the nucleus after exposure to shedding stimuli and HB-
EGF-C is responsible for various functions [10]. However,
the details of how HB-EGF-C actually works in human
gastric cancer remain unclear. Thus, we analyzed the rela-
tionship between expression and localization of HB-EGF
and clinical behavior by using human gastric cancer speci-
mens. Furthermore, we constructed mutated HB-EGF atrin-binding epidermal growth factor-like growth factor (proHB-EGF)
F (HB-EGF-CTF) after ectodomain shedding. sHB-EGF binds to EGFR as
ocates from plasma membrane to the nucleus after shedding and the
pressors in the nucleus. Moreover, unshed proHB-EGF translocates to
F and proHB-EGF.
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to the nucleus after shedding [10], and 2 gastric cancer
cell lines that stably overexpressed full-length HB-EGF
and HB-EGF-mC. We verified the significance of HB-
EGF-C in gastric cancer by using these gastric cancer cell
lines.
We herein demonstrate that the nuclear translocation
of HB-EGF-C is critical for the invasion and progression
of human gastric cancer.Results
Patient Characteristics
Characteristics of patients in this study are shown in
Table 1. Subjects included 96 patients, with 59 men and
37 women. The median age was 69 years (range, 37–
91 years), and histological types included intestinal type
in 59 patients and diffuse type in 37 patients. According
to the Union for International Cancer Control (UICC)
tumor-node-metastasis (TNM) classification, the stage
of primary tumor was pT1 in 19 cases, pT2 in 44 cases,
pT3 in 22 cases, and pT4 in 11 cases.HB-EGF-C expression in human gastric cancer
Immunoreactivity for HB-EGF-C was categorized into 3
patterns: staining of nucleus and cytoplasm for HB-EGF-
C, staining of only the cytoplasm for HB-EGF, or no
staining (Figure 2). Intracellular localization for HB-EGF
was consistent with that of HB-EGF-C in all cases, but
the nuclear immunoreactive rate for HB-EGF was clearly
low compared with HB-EGF-C. Hence, HB-EGF-C
immunoreactivity in the cytoplasm reflected proHB-EGF
expression and HB-EGF-C immunoreactivity in the nu-
cleus reflected nuclear localization of HB-EGF-CTF and
proHB-EGF.
The immunohistochemical analysis of HB-EGF-C in
human gastric cancer according to clinical stage is
shown in Table 2. Of the 96 gastric cancer cases exam-
ined, HB-EGF-C staining was detected in 44 casesTable 1 Characteristics of gastric cancer patients who
underwent gastrectomy
Total no. of patients 96
Gender Male 59
Female 37
Age (years) Median 69
(range) (37–91)
Histological type Intestinal type 59
Diffuse type 37
Stage of primary tumor (pT1/pT2/pT3/pT4) (19/44/22/11)
(UICC-TNM)
UICC-TNM, Seventh edition of the Union for International Cancer Control
tumor-node-metastasis classification.(45.8 %). Among the 44 cases with HB-EGF-C-positive
staining, 25 cases (26.0 %) exhibited staining in both the
nucleus and in the cytoplasm; however, 19 cases (19.8 %)
exhibited staining only in the cytoplasm.
Of 63 cases with pT1 and pT2, HB-EGF-C immunor-
eactivity was detected in 7 cases (11.1 %) in the nucleus
and the cytoplasm and in 15 (23.8 %) in the cytoplasm
only, but it was not observed in 41 cases (65.1 %). How-
ever, among 33 cases with pT3 and pT4, 12 (36.4 %)
showed HB-EGF-C staining in the nucleus and in the
cytoplasm, 10 (30.3 %) showed staining in the cytoplasm
only, and 11 (33.3 %) did not exhibit immunoreactivity
for HB-EGF-C. HB-EGF-C expression was significantly
increased in cases with stage pT3 and pT4 compared to
those with pT1 and pT2 (P< 0.01), and nuclear expres-
sion for HB-EGF-C was also significantly increased in
cases with stage pT3 and pT4 (P< 0.01). These results
suggest that not only proHB-EGF expression, but also
nuclear translocation of proHB-EGF and HB-EGF-CTF
may play crucial roles in gastric cancer invasion.
Expression and intracellular localization of HB-EGF-C in
each gastric cancer cell line
To examine the role of nuclear HB-EGF-C in gastric
cancer cells, we established KATO III stable cell lines
that express wt-HB-EGF or HB-EGF-mC. We first evalu-
ated the protein levels of proHB-EGF and HB-EGF-CTF
in KATO III/mock, KATO III/wt-HB-EGF cells, and
KATO III/HB-EGF-mC cells by Western blotting (Fig-
ure 3A). KATO III/wt-HB-EGF cells and KATO III/HB-
EGF-mC cells expressed significant levels of proHB-EGF,
and proHB-EGF expression decreased and HB-EGF-CTF
was generated by shedding of proHB-EGF with 12-O-
tetradecanoylphorbol-13-acetate (TPA).
We next investigated the intracellular localization of
HB-EGF-C in KATO III/wt-HB-EGF cells and KATO
III/HB-EGF-mC cells by using an immunofluorescent
microscope (Figure 3B). HB-EGF-C translocated from
the cytoplasm to the nucleus by adding TPA to activate
the processing of proHB-EGF in KATO III/wt-HB-EGF
cells, but HB-EGF-C did not accumulate in the nucleus
after TPA treatment in KATO III/HB-EGF-mC cells.
Meanwhile, TPA induced EGFR phosphorylation in both
KATO III/wt-HB-EGF cells and KATO III/HB-EGF-mC
cells, and EGFR phosphorylation was inhibited by adding
of 10 μg/ml cetuximab (Figure 3C).
We thus confirmed that HB-EGF in KATO III/wt-HB-
EGF cells has both functions as an EGFR ligand and
HB-EGF-C nuclear translocation, but that of KATO
III/HB-EGF-mC has only function as an EGFR ligand
without HB-EGF-C nuclear translocation. We also con-
firmed the same results relating three established forms
of MKN45 cells (MKN45/mock, MKN45/wt-HB-EGF,
MKN45/HB-EGF-mC) (Data not shown). Using these
Figure 2 Immunohistochemistry in human gastric cancer. Heparin-binding epidermal growth factor-like growth factor (HB-EGF) expression
was immunohistochemically investigated using samples of surgically resected gastric cancer cells. Cells were immunostained using anti-HB-EGF
antibody and anti-HB-EGF-C antibody. Representative positive staining cells were shown by black arrows. (Upper pictures) HB-EGF and HB-EGF-C
were detected in the cytoplasm and nucleus of gastric cancer cells. (Middle pictures) HB-EGF and HB-EGF-C were detected in only the cytoplasm
of gastric cancer cells. (Lower pictures) HB-EGF and HB-EGF-C were not detected in gastric cancer cells. (Original magnification: ×400).
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EGF-C in gastric cancer cells.HB-EGF-C nuclear translocation promotes gastric cancer
cell growth
Cell growth curves in 3 cancer cell lines are shown in
Figure 4A. The growth of KATO III/wt-HB-EGF andTable 2 HB-EGF-C expression and localization according
to clinical stage
Expression (+)* (−)
Localization C (+) N (+) C (+) N (−) C (−) N (−) Total (n)
pT1, 2 7 (11.1)** 15 (23.8) 41 (65.1) 63
n, (%)
pT3, 4 12 (36.4)** 10 (30.3) 11 (33.3) 33
n, (%)
Total 19 (19.8) 25 (26.0) 52 (54.2) 96
n, (%)
C, cytoplasm; N, nucleus; (+), positive staining; (−), negative staining.
* P< 0.01, pT3, 4 vs. pT1, 2 for the rate of C (+) N (+) and C (+) N (−).
** P< 0.01, pT3, 4 vs. pT1, 2 for the rate of C (+) N (+).KATO III/HB-EGF-mC cells was significantly faster than
that of KATOIII/mock cells, and the growth of KATO
III/HB-EGF-mC cells was significantly decreased com-
pared with KATO III/wt-HB-EGF cells. The same results
were observed in three forms of MKN45 cells (Add-
itional file 1: Figure S1A). These results demonstrate
that both conventional signals of HB-EGF as an EGFR
ligand and a novel signal for HB-EGF-C nuclear trans-
location are critical for gastric cancer cell proliferation.
HB-EGF-C nuclear translocation promotes cell invasion
and wound healing
To verify the present results by using clinical samples,
we next investigated whether HB-EGF-C nuclear trans-
location causes an increase in the migration of gastric
cancer cells. Three gastric cancer cell lines were used in
a transwell invasion assay. As shown in Figure 4B,
KATO III/wt-HB-EGF showed a obvious increase in in-
vasion compared with KATO III/mock cells, whereas
KATO III/HB-EGF-mC cells did a slight increase. More-
over, KATO III/HB-EGF-mC cells showed a significant
decrease in invasion compared with KATO III/wt-HB-
Figure 3 Characteristics of KATO III/wt-HB-EGF and KATO III/HB-EGF-mC cells. A) Western blot analysis of proHB-EGF and HB-EGF-CTF
expression in 3 gastric cancer cell lines. Anti-HB-EGF antibody was used to recognize the proHB-EGF ectodomain and anti-HB-EGF-C antibody was
used to recognize the cytoplasmic region of proHB-EGF. Each lane contains 100 μg of protein. Cleavage of proHB-EGF was stimulated using 200
nM TPA. B) HB-EGF-C localization after TPA-inducible processing of proHB-EGF in KATO III/wt-HB-EGF and KATO III/HB-EGF-mC cells by
immunofluorescence microscopy. Nuclei were stained blue with DAPI, and HB-EGF-C were stained red with anti-HB-EGF-C antibody. Cells were
stimulated with 200 nM TPA for 60 min. C) Western blot analysis of EGFR phosphorylation induced by TPA (200 nM) with or without cetuximab
(10 μg/ml) in KATO III/wt-HB-EGF and KATO III/HB-EGF-mC.
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parison with KATO III cells, the same results were
observed in three forms of MKN45 cells (Additional file
1: Figure S1B).
Wound healing assays have been employed to study
cell polarization or tissue matrix remodeling or to esti-
mate cell proliferation and migration rates. HB-EGF is
well known to be upregulated in the wound healing
process of certain cell types, including keratinocytes
[11,12]. We studied the effect of HB-EGF on wound
healing by using 3 gastric cancer cell lines (Figure 4C,
D). The effectiveness of wound healing was observed in
KATO III/wt-HB-EGF, but no significant effect was
observed in KATO III/HB-EGF-mC. Although a little
wound healing effect was observed in MKN45/HB-EGF-
mC, the same tendency as KATO III cells was observed
in MKN45 cells (Additional file 1: Figure S1C, D). These
results suggest that HB-EGF-C nuclear translocation ra-
ther than HB-EGF as an EGFR ligand is critical for gas-
tric cancer cell migration.
Discussion
EGFR and EGFR ligands have been extensively studied
because the inactivation of EGFR represents a promisingstrategy for the treatment of several cancers [13]. How-
ever, there have been no studies regarding the actions of
proHB-EGF and HB-EGF-CTF induced by the cleavage
of EGFR ligands. We previously reported that nuclear
translocation of HB-EGF-CTF results in a unique signal
transduction pathway for cell growth [6,7,10,14]. In the
present study, we demonstrated the role of HB-EGF-C
in human gastric cancer.
Of the EGFR ligands, HB-EGF is considered the most
important growth factor because HB-EGF-knockout
mice die shortly after birth, in contrast to the effects of
other EGFR ligands [15]. HB-EGF, which is an inducer
of tumor growth and angiogenesis, induces resistance
to chemotherapy [16,17]. The expression of HB-EGF
has been demonstrated in many human cancers, such
as hepatocellular carcinoma [18], pancreatic cancer
[19], gastric cancer [20,21], colorectal cancer [22], and
ovarian cancer [23]. In human gastric cancer, a previ-
ous study reported that HB-EGF immunoreactivity was
detected in 61 to 72 % of cancer cells and was gener-
ally stronger in deeply invasive cancer cells than in
cancer cells of more superficial layers [20,21]. More-
over, a recent report suggested that HB-EGF promoted
peritoneal carcinomatosis from gastric cancer [24]. HB-
Figure 4 Cell proliferation and migration in KATO III/mock, KATO III/wt-HB-EGF and KATO III/HB-EGF-mC cells. A) Cell proliferation assay.
Mean of 3 independent clones; bars, SD;* P< 0.01, as compared with KATO III/mock; **P< 0.05. B) Transwell invasion assay was analyzed in each cell
at 48 h after 200 nM TPA stimulation. Value of KATO-III/mock cells was arbitrarily defined as 1. Mean of 3 independent clones; bars, SD;* P< 0.01, as
compared with KATO III/mock; **P< 0.05, as compared with KATO III/mock; ***P< 0.05. C) Wound healing assay. Confluent monolayers of each gastric
cancer cells were mechanically wounded with a pipette tip, and photos were obtained at 0 h and 24 h after stimulation of 200 nM TPA (Original
magnification: ×40). D) Quantification of wound healing assay in 3 independent clones. Migration rate of KATO-III/mock cells at 24 h after TPA
stimulation was arbitrarily defined as 1. Mean of 3 independent clones; bars, SD* P< 0.01, as compared with KATO III/mock; **P< 0.01.
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gastric cancer.
In the present study, proHB-EGF expression was
observed in 45.8 % of human gastric cancer cases, par-
ticularly in deeply invasive gastric cancer. This frequency
was slightly lower than the previous reports [20,21], but
it is considered that positive for both anti-HB-EGF and
anti-HB-EGF-C antibodies was defined as HB-EGF-posi-
tive in the present study. Notably, we observed nuclear
expression of HB-EGF-C in deep gastric cancers (pT3
and pT4).
In order to confirm the relationship between invasion
and HB-EGF-C nuclear localization that had been
demonstrated in clinical experiments, we successfully
constructed gastric cancer cell lines with and without
HB-EGF-C nuclear translocation by overexpressing wt-
HB-EGF and HB-EGF-mC. We were thus able to se-
lectively analyze the fundamental effects of HB-EGF-C
nuclear translocation in vitro.
The present study showed that both the function of
HB-EGF as an EGFR ligand and HB-EGF-C nuclear
translocation induce gastric cancer growth, whereas HB-EGF-C nuclear translocation independently plays a crit-
ical role in gastric cancer invasion. Hence, the present
in vitro findings support the data of clinical experiments.
Recent studies have shown that the inhibition of proHB-
EGF shedding promoted cell-cell interactions and
decreased cell migration [25,26]. HB-EGF-C signals in
the present study may involve these previous results
related to cell migration.
Nuclear staining of HB-EGF is reportedly a progressive
and poor prognostic factor in bladder cancer [27,28].
Nuclear translocation of proHB-EGF and HB-EGF-CTF
might be the factor responsible for this phenomenon be-
cause an antibody against HB-EGF-C was used in these
studies. Our study showed that nuclear HB-EGF-C is an
important progressive factor in gastric cancer as well as
in bladder cancer. We cannot precisely elucidate which
of proHB-EGF and HB-EGF-CTF has more responsibil-
ity for gastric cancer invasion. However, we can specu-
late that HB-EGF-CTF would be involved more than
proHB-EGF, because much HB-EGF-CTF yield after
shedding of proHB-EGF that is necessary for HB-EGF-C
nuclear translocation. Further investigation is necessary,
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CTF in the nucleus and the detailed mechanisms indu-
cing cell migration are not yet fully understood; clarifying
these mechanisms may result in the development of new
cancer therapies.
Conclusions
The present study showed that HB-EGF-C nuclear
translocation is involved in gastric cancer development,
in addition to the conventional function of HB-EGF as
an EGFR ligand. HB-EGF-C nuclear translocation may
offer a prognostic marker and a new molecular target
for gastric cancer therapy.
Methods
Materials
Anti-HB-EGF-C antibody was used to recognize HB-
EGF-C, as previously described [7], and anti-HB-EGF
antibody (R&D Systems, Minneapolis, MN) was used to
recognize the proHB-EGF ectodomain. Cetuximab
((Merk, Darmstadt, Germany)), a monoclonal antibody
to EGFR, was used to inhibit EGFR phosphorylation.
Immunohistochemistry
Immunohistochemical staining was performed using
anti-HB-EGF antibody and anti-HB-EGF-C antibody.
Consecutive 4-μm-thick sections were deparaffinized
and hydrated through a graded series of alcohols. After
inhibiting endogenous peroxidase activity by immersion
in a 3 % H2O2/methanol solution, antigen retrieval was
achieved by heating the samples in 10 mM citrate buffer
(pH 6.0) in a microwave oven for 10 min at 98 °C. Next,
sections were incubated overnight with primary anti-
bodies. After thorough washing in PBS (−), the samples
were incubated with biotinylated secondary antibodies
and then with avidin-biotin-horseradish peroxidase com-
plexes (Vectastain Elite ABC kit; Vector Laboratories,
Burlingame, CA). Finally, immune complexes were
visualized by incubation in 0.01 % H2O2 and 0.05 %
3,3′-diaminobenzidine tetrachloride. Nuclear counter-
staining was accomplished with Mayer’s hematoxylin.
Clinical patients and assessment
Using information from a computerized database, we
obtained gastric cancer specimens from 96 patients who
had undergone surgical operations for gastric adenocar-
cinoma between January 2002 and December 2006 at
the Nagoya City University Hospital. Written general
consent that included research uses of clinical data had
been obtained from all patients. The study was per-
formed in accordance with the Declaration of Helsinki
and Japanese ethical guidelines for epidemiological re-
search. We obtained an institutional review board (IRB)
waiver to conduct this study from the chairperson of theIRB. All 96 patients were histologically diagnosed with
gastric cancer. Clinical stage was determined according
to the Seventh edition of the UICC-TNM classification
[29]. All immunostained specimens were assessed by 2
investigators who were blinded to all clinical informa-
tion. When more than 10 % of the cancer cells in each
section were stained for both anti-HB-EGF antibody and
anti-HB-EGF-C antibody, immunostaining was defined
as positive.
Cell culture
We used KATO III and MKN45 gastric cancer cell line
(Japan Health Science Research Resources Bank, Tokyo,
Japan) in our investigation. KATO III and MKN45 cells
were maintained in RPMI1640 (Sigma-Aldrich Co., St.
Louis, MO) medium that was supplemented with 10 %
fetal bovine serum (FBS). Cells were cultured at 37 °C in
5 % CO2 humidified air.
Transfection
cDNAs encoding wild-type HB-EGF (wt-HB-EGF) and
the mutant that carry a point mutation at K201A of the
C-terminus (HB-EGF-mC) [10] were subcloned into
pME18SIII with hygromycin-resistance gene. As previ-
ously shown, HB-EGF-mC does not translocate from the
plasma membrane to the nucleus after TPA stimulation.
All cDNA constructs were verified by DNA sequencing
using a CEQ 8000 DNA Analysis System (Beckman
Coulter, Brea, CA).
The KATO III human gastric cancer cell line was trans-
fected with wt-HB-EGF (KATO III/wt-HB-EGF) and HB-
EGF-mC (KATOIII/HB-EGF-mC) by using Lipofectamine
2000 (Invitrogen, Carlsbad, CA), according to the manu-
facturer’s instructions, and stably transfected clones were
isolated using hygromycin B (Invitrogen). As a control,
KATO III was transfected with an empty plasmid (KATO
III/mock). As well as KATO III cells, MKN45/wt-HB-
EGF, MKN45/HB-EGF-mC and MKN45/mock cells were
established. These cells were maintained in RPMI1640
medium that was supplemented with 10 % FBS and
800 μg/mL hygromycin B.
Immunofluorescence microscopy
Samples were fixed with ethanol and acetone and incu-
bated with primary antibodies against HB-EGF-C. Second-
ary antibodies was Alexa FluorW 594 goat anti-rabbit IgG
(H+L) (Invitrogen). All sections were counterstained with
DAPI (KPL, Inc., Gaithersburg, MD). Images were
obtained using an Eclipse 80i fluorescent microscope
(Nikon, Tokyo, Japan).
Each gastric cancer cell in a subconfluent state was
placed in serum-free medium for 24 h and stimulated
with 200 nM TPA (Cell Signaling Technology, Danvers,
MA) for 60 min. Cells were stimulated by TPA in order
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proHB-EGF [30], and the intracellular localization of
HB-EGF-C was then analyzed by immunofluorescence.
Western blotting
Cells were washed with PBS and subsequently dissolved
in 1× cell lysis buffer (Cell Signaling Technology) con-
taining 20 mM Tris–HCl (pH 7.5), 150 mM NaCl,
1 mM Na2EDTA, 1 mM EGTA, 1 % Triton, 2.5 mM so-
dium pyrophosphate, 1 mM β-glycerophosphate, 1 mM
Na3VO4, and 1 μg/mL leupeptin. After disruption in an
ice bath by using a Bio-ruptor sonicator (Cosmo Bio,
Tokyo, Japan) for 15 s, lysates were centrifuged at
15,000 rpm for 10 min at 4°C. Each sample was normal-
ized against an equal protein concentration by using a
protein assay kit (Bio-Rad Laboratories, Hercules, CA).
A equal quantity of 2× sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis (SDS-PAGE) sample buffer
(0.5 mol/L Tris–HCl, pH 7.2, 1 % SDS, 100 mmol/L β-
mercaptoethanol, and 0.01 % bromophenol blue) was
added to each sample and boiled for 5 min at 100°C. Ali-
quots of sample were fractionated on 10 or 15 % SDS-
PAGE and then electroblotted onto a nitrocellulose
membrane. The membrane was blocked with 5 %
skimmed milk in PBS for 1 h at room temperature. The
membrane was incubated with the primary antibodies
for HB-EGF-C, HB-EGF, EGFR (MILLIPORE, Temecula,
CA) or phospho-EGFR (MILLIPORE) overnight at 4°C
and then washed with 0.05 % Tween 20 in PBS 3 times
at 5-min intervals. The membrane was incubated with
secondary antibody for 1 h at room temperature, which
was followed by 3 washes with 0.05 % Tween 20 in PBS
3 times at 5-min intervals. The membrane was treated
with enhanced chemiluminescence detection reagents
(ECL; Amersham, Arlington Heights, IL) for 1 min at
room temperature and then exposed to scientific im-
aging films (Eastman Kodak, Rochester, NY). Proteins
were visualized as bands on the images. Filters were
stripped and reprobed with monoclonal β-actin antibody
(Abcam plc, Tokyo, Japan) as an internal control.
Cell proliferation assay
Proliferation assays were performed as follows. Cells
were seeded at 2.0 × 104 cells in the medium with 10 %
FBS on 6-cm diameter dishes. Cells were counted on
days 3, 5, and 8 by using an Automatic Cell Counter
(Millipore, Billerica, MA). Each experiment was con-
ducted independently in cell lines isolated from 3 inde-
pendent clones.
Wound healing assay
A wound healing assay was conducted in order to
measure cell motility. Cells were grown to confluence in
6-well plates and serum-starved for 24 h, and then across-shaped wound was made on the monolayers by
using a sterile 200-μL pipette tip. Cells were washed
with PBS, placed in the same media with 200nM TPA,
and the cross-shaped wound was photographed under
microscope at 0 h and 24 h.
Transwell invasion assay
Cell migration was assessed using the Cell Invasion
Assay (CULTREX, Gaithersburg, MD), which consists of
a 96-well transwell tissue culture plate with an 8-μm
pore size membranes coated with matrigel (top cham-
ber) and a black receiver plate compatible with a 96-well
fluorescent plate reader (bottom chamber). After 24 h of
serum starvation, cells (5000 cells/well) in serum-free
medium with 200nM TPA were placed in the top cham-
ber, and medium containing 10 % FBS was added to the
bottom chamber. After 48 h of incubation in CO2 at 37°
C, the cells that had invaded the bottom chamber were
measured according to the manufacturer’s instructions.
Each experiment was conducted in cell lines which was
isolated from 3 independent clones.
Statistical analysis
Values are expressed as the mean ± SD. Data were ana-
lyzed using χ2 test as appropriate. Multiple comparison
was done using Games-Howell’s method. P-values< 0.05
were considered statistically significant. Data analyses
were performed using Dr. SPSS II for Windows release
11.0.1 J software (SPSS Japan, Tokyo, Japan).
Additional file
Additional file 1: Figure S1 Cell proliferation and migration in MKN45/
mock, MKN45/wt-HB-EGF and MKN45/HB-EGF-mC cells. A) Cell
proliferation assay. Mean of 3 independent clones; bars, SD;* P< 0.01, as
compared with MKN45/mock; **P< 0.01. B) Transwell invasion assay was
analyzed in each cell at 48 h after 200 nM TPA stimulation. Value of
MKN45/mock cells was arbitrarily defined as 1. Mean of 3 independent
clones; bars, SD;* P< 0.01, as compared with KATO III/mock; **P< 0.05, as
compared with KATO III/mock; ***P< 0.05. C) Wound healing assay.
Confluent monolayers of each gastric cancer cells were mechanically
wounded with a pipette tip, and photos were obtained at 0 h and 24 h
after stimulation of 200 nM TPA (Original magnification: ×40). D)
Quantification of wound healing assay in 3 independent clones.
Migration rate of MKN45/mock cells at 24 h after TPA stimulation was
arbitrarily defined as 1. Mean of 3 independent clones; bars, SD* P< 0.01,
as compared with MKN45/mock; **P< 0.05, as compared with MKN45/
mock; ***P< 0.01.
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Shimura et al. BMC Cancer 2012, 12:205 Page 9 of 10
http://www.biomedcentral.com/1471-2407/12/205cancer cell line transfected with HB-EGF-mC; KATO III/mock: KATO III human
gastric cancer cell line transfected with an empty plasmid; MKN45/wt-HB-
EGF: MKN45 human gastric cancer cell line transfected with wt-HB-EGF;
MKN45/HB-EGF-mC: MKN45 human gastric cancer cell line transfected with
HB-EGF-mC; MKN45/mock: MKN45 human gastric cancer cell line transfected
with an empty plasmid; FBS: Fetal bovine serum; TPA: 12-O-
tetradecanoylphorbol-13-acetate.
Competing interests
All the authors declare that we have no competing interests.
Acknowledgments
We wish to thank Yukimi Hashidume for technical assistance. This study was
supported by the Ministry of Education, Culture, Sports, Science and
Technology of Japan (No. 22790665).
Author details
1Department of Gastroenterology and Metabolism, Nagoya City University
Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku,
Nagoya, 467-8601, Japan. 2Department of Biochemistry and Molecular
Genetics, Ehime University Graduate School of Medicine, Shitsukawa, Toon,
Ehime, 791-0295, Japan. 3Department of Cell Growth and Tumor Regulation,
Proteo-Medicine Research Center, Ehime University, Shitsukawa, Toon, Ehime,
791-0295, Japan.
Author’s contributions
Conception and design, TS; Acquisition of data, TS, MY, TM, and TK; Analysis
and interpretation of data, TS; Drafting of the manuscript, TS; Revising it
critically for important intellectual content, SF and SH; Final approval of the
version to be published, TJ; Acquisition of funding, TS; General supervision of
research group, SH and TJ. All authors read and approved the final
manuscript.
Received: 17 December 2011 Accepted: 30 May 2012
Published: 30 May 2012
References
1. International Agency for Research on Cancer GLOBOCAN 2008:: ; http://
globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900 (last accessed
on December 16, 2011).
2. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A,
Lordick F, Ohtsu A, Omuro Y, Satoh T, et al: Trastuzumab in combination
with chemotherapy versus chemotherapy alone for treatment of HER2-
positive advanced gastric or gastro-oesophageal junction cancer
(ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010,
376:687–697.
3. Higashiyama S, Iwabuki H, Morimoto C, Hieda M, Inoue H, Matsushita N:
Membrane-anchored growth factors, the epidermal growth factor family:
beyond receptor ligands. Cancer Sci 2008, 99:214–220.
4. Normanno N, Bianco C, De Luca A, Maiello MR, Salomon DS: Target-based
agents against ErbB receptors and their ligands: a novel approach to
cancer treatment. Endocr Relat Cancer 2003, 10:1–21.
5. Salomon DS, Brandt R, Ciardiello F, Normanno N: Epidermal growth factor-
related peptides and their receptors in human malignancies. Crit Rev
Oncol Hematol 1995, 19:183–232.
6. Kinugasa Y, Hieda M, Hori M, Higashiyama S: The carboxyl-terminal
fragment of pro-HB-EGF reverses Bcl6-mediated gene repression. J Biol
Chem 2007, 282:14797–14806.
7. Nanba D, Mammoto A, Hashimoto K, Higashiyama S: Proteolytic release of
the carboxy-terminal fragment of proHB-EGF causes nuclear export of
PLZF. J Cell Biol 2003, 163:489–502.
8. Hirata Y, Ogasawara N, Sasaki M, Mizushima T, Shimura T, Mizoshita T, Mori
Y, Kubota E, Wada T, Tanida S, et al: BCL6 degradation caused by the
interaction with the C-terminus of pro-HB-EGF induces cyclin D2
expression in gastric cancers. Br J Cancer 2009, 100:1320–1329.
9. Shimura T, Kataoka H, Ogasawara N, Kubota E, Sasaki M, Tanida S, Joh T:
Suppression of proHB-EGF carboxy-terminal fragment nuclear
translocation: a new molecular target therapy for gastric cancer. Clin
Cancer Res 2008, 14:3956–3965.
10. Hieda M, Isokane M, Koizumi M, Higashi C, Tachibana T, Shudou M, Taguchi
T, Hieda Y, Higashiyama S: Membrane-anchored growth factor, HB-EGF,on the cell surface targeted to the inner nuclear membrane. J Cell Biol
2008, 180:763–769.
11. Tokumaru S, Higashiyama S, Endo T, Nakagawa T, Miyagawa JI, Yamamori K,
Hanakawa Y, Ohmoto H, Yoshino K, Shirakata Y, et al: Ectodomain
shedding of epidermal growth factor receptor ligands is required for
keratinocyte migration in cutaneous wound healing. J Cell Biol 2000,
151:209–220.
12. Marikovsky M, Breuing K, Liu PY, Eriksson E, Higashiyama S, Farber P,
Abraham J, Klagsbrun M: Appearance of heparin-binding EGF-like growth
factor in wound fluid as a response to injury. Proc Natl Acad Sci USA 1993,
90:3889–3893.
13. Hynes NE, Lane HA: ERBB receptors and cancer: the complexity of
targeted inhibitors. Nat Rev Cancer 2005, 5:341–354.
14. Nanba D, Inoue H, Shigemi Y, Shirakata Y, Hashimoto K, Higashiyama S: An
intermediary role of proHB-EGF shedding in growth factor-induced c-
Myc gene expression. J Cell Physiol 2008, 214:465–473.
15. Iwamoto R, Yamazaki S, Asakura M, Takashima S, Hasuwa H, Miyado K,
Adachi S, Kitakaze M, Hashimoto K, Raab G, et al: Heparin-binding EGF-like
growth factor and ErbB signaling is essential for heart function. Proc Natl
Acad Sci USA 2003, 100:3221–3226.
16. Wang F, Liu R, Lee SW, Sloss CM, Couget J, Cusack JC: Heparin-binding
EGF-like growth factor is an early response gene to chemotherapy and
contributes to chemotherapy resistance. Oncogene 2007, 26:2006–2016.
17. Ongusaha PP, Kwak JC, Zwible AJ, Macip S, Higashiyama S, Taniguchi N,
Fang L, Lee SW: HB-EGF is a potent inducer of tumor growth and
angiogenesis. Cancer Res 2004, 64:5283–5290.
18. Inui Y, Higashiyama S, Kawata S, Tamura S, Miyagawa J, Taniguchi N,
Matsuzawa Y: Expression of heparin-binding epidermal growth factor in
human hepatocellular carcinoma. Gastroenterology 1994, 107:1799–1804.
19. Kobrin MS, Funatomi H, Friess H, Buchler MW, Stathis P, Korc M: Induction
and expression of heparin-binding EGF-like growth factor in human
pancreatic cancer. Biochem Biophys Res Commun 1994, 202:1705–1709.
20. Murayama Y, Miyagawa J, Shinomura Y, Kanayama S, Isozaki K, Yamamori K,
Mizuno H, Ishiguro S, Kiyohara T, Miyazaki Y, et al: Significance of the
association between heparin-binding epidermal growth factor-like
growth factor and CD9 in human gastric cancer. Int J Cancer 2002,
98:505–513.
21. Naef M, Yokoyama M, Friess H, Buchler MW, Korc M: Co-expression of
heparin-binding EGF-like growth factor and related peptides in human
gastric carcinoma. Int J Cancer 1996, 66:315–321.
22. Kopp R, Rothbauer E, Ruge M, Arnholdt H, Spranger J, Muders M, Pfeiffer
DG, Schildberg FW, Pfeiffer A: Clinical implications of the EGF receptor/
ligand system for tumor progression and survival in gastrointestinal
carcinomas: evidence for new therapeutic options. Recent Results Cancer
Res 2003, 162:115–132.
23. Yagi H, Miyamoto S, Tanaka Y, Sonoda K, Kobayashi H, Kishikawa T, Iwamoto
R, Mekada E, Nakano H: Clinical significance of heparin-binding epidermal
growth factor-like growth factor in peritoneal fluid of ovarian cancer. Br J
Cancer 2005, 92:1737–1745.
24. Yasumoto K, Yamada T, Kawashima A, Wang W, Li Q, Shterev DI, Tacheuchi
S, Mouri H, Yamashita K, Ohtsubo K, Yano S: The EGFR ligands
Amphiregulin and Heparin-binding EGF-like growth factor promote
peritoneal carcinomatosis in CXCR4-expressing gastric cancer. Clin Cancer
Res 2011, 17:3619–3630.
25. Wang F, Sloss C, Zhang X, Lee SW, Cusack JC: Membrane-bound heparin-
binding epidermal growth factor like growth factor regulates E-cadherin
expression in pancreatic carcinoma cells. Cancer Res 2007, 67:8486–8493.
26. Singh AB, Tsukada T, Zent R, Harris RC: Membrane-associated HB-EGF
modulates HGF-induced cellular responses in MDCK cells. J Cell Sci 2004,
117:1365–1379.
27. Kramer C, Klasmeyer K, Bojar H, Schulz WA, Ackermann R, Grimm MO:
Heparin-binding epidermal growth factor-like growth factor isoforms and
epidermal growth factor receptor/ErbB1 expression in bladder cancer
and their relation to clinical outcome. Cancer 2007, 109:2016–2024.
28. Adam RM, Danciu T, McLellan DL, Borer JG, Lin J, Zurakowski D, Weinstein MH,
Rajjayabun PH, Mellon JK, Freeman MR: A nuclear form of the heparin-
binding epidermal growth factor-like growth factor precursor is a feature
of aggressive transitional cell carcinoma. Cancer Res 2003, 63:484–490.
29. Sobin L, Gospodarowicz M, Wittekind C: TNM classification of malignant
tumours. In. 7th editionEdited by Hoboken NJ.: John Wiley & Sons, Inc;
2009.
Shimura et al. BMC Cancer 2012, 12:205 Page 10 of 10
http://www.biomedcentral.com/1471-2407/12/20530. Goishi K, Higashiyama S, Klagsbrun M, Nakano N, Umata T, Ishikawa M,
Mekada E, Taniguchi N: Phorbol ester induces the rapid processing of cell
surface heparin-binding EGF-like growth factor: conversion from
juxtacrine to paracrine growth factor activity. Mol Biol Cell 1995, 6:967–980.
doi:10.1186/1471-2407-12-205
Cite this article as: Shimura et al.: Nuclear translocation of the
cytoplasmic domain of HB-EGF induces gastric cancer invasion. BMC
Cancer 2012 12:205.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
